KRAS G12C mutated advanced non-small cell lung cancer (NSCLC): Characteristics, treatment patterns and overall survival from a Danish nationwide observational register study
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
KRAS G12C mutated advanced non-small cell lung cancer (NSCLC) : Characteristics, treatment patterns and overall survival from a Danish nationwide observational register study. / Frost, Matilde Grupe; Jensen, Kristoffer Jarlov; Gotfredsen, Ditte Resendal; Sørensen, Anne Mette Skov; Ankarfeldt, Mikkel Zöllner; Louie, Karly S.; Sroczynski, Nicholas; Jakobsen, Erik; Andersen, Jon Lykkegaard; Jimenez-Solem, Espen; Petersen, Tonny Studsgaard.
In: Lung Cancer, Vol. 178, 2023, p. 172-182.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - KRAS G12C mutated advanced non-small cell lung cancer (NSCLC)
T2 - Characteristics, treatment patterns and overall survival from a Danish nationwide observational register study
AU - Frost, Matilde Grupe
AU - Jensen, Kristoffer Jarlov
AU - Gotfredsen, Ditte Resendal
AU - Sørensen, Anne Mette Skov
AU - Ankarfeldt, Mikkel Zöllner
AU - Louie, Karly S.
AU - Sroczynski, Nicholas
AU - Jakobsen, Erik
AU - Andersen, Jon Lykkegaard
AU - Jimenez-Solem, Espen
AU - Petersen, Tonny Studsgaard
N1 - Publisher Copyright: © 2023 Elsevier B.V.
PY - 2023
Y1 - 2023
N2 - Objectives: We aimed to characterize the advanced NSCLC population in terms of KRAS G12C prevalence, patient characteristics, and survival outcomes after the introduction of immunotherapies. Materials and Methods: We identified adult patients diagnosed with advanced NSCLC between January 1, 2018 and June 30, 2021 using the Danish health registries. Patients were grouped by mutational status (any KRAS mutation, KRAS G12C, and KRAS/EGFR/ALK wildtype [Triple WT]). We analyzed KRAS G12C prevalence, patient and tumor characteristics, treatment history, time-to-next-treatment (TTNT), and overall survival (OS). Results: We identified 7,440 patients of whom 40% (n = 2,969) were KRAS tested prior to the first line of therapy (LOT1). Among the KRAS tested, 11% (n = 328) harbored KRAS G12C. More KRAS G12C patients were women (67%), smokers (86%), had a high (≥50%) level of PD-L1 expression (54%), and more frequently received anti-PD-L1 treatment than any other group. From the date of the mutational test result, OS (7.1–7.3 months) was similar between the groups. OS from LOT1 (14.0 months) and LOT2 (10.8 months), and TTNT from LOT1 (6.9 months) and LOT2 (6.3 months) was numerically longer for the KRAS G12C mutated group compared to any other group. However, from LOT1 and LOT2, the OS and TTNT were comparable when stratifying the groups by PD-L1 expression level. Regardless of the mutational group, OS was markedly longer for patients with high PD-L1 expression. Conclusion: In patients diagnosed with advanced NSCLC after the implementation of anti-PD-1/L1 therapies, the survival in KRAS G12C mutated patients is comparable to patients with any KRAS mutation, Triple WT, and all NSCLC patients.
AB - Objectives: We aimed to characterize the advanced NSCLC population in terms of KRAS G12C prevalence, patient characteristics, and survival outcomes after the introduction of immunotherapies. Materials and Methods: We identified adult patients diagnosed with advanced NSCLC between January 1, 2018 and June 30, 2021 using the Danish health registries. Patients were grouped by mutational status (any KRAS mutation, KRAS G12C, and KRAS/EGFR/ALK wildtype [Triple WT]). We analyzed KRAS G12C prevalence, patient and tumor characteristics, treatment history, time-to-next-treatment (TTNT), and overall survival (OS). Results: We identified 7,440 patients of whom 40% (n = 2,969) were KRAS tested prior to the first line of therapy (LOT1). Among the KRAS tested, 11% (n = 328) harbored KRAS G12C. More KRAS G12C patients were women (67%), smokers (86%), had a high (≥50%) level of PD-L1 expression (54%), and more frequently received anti-PD-L1 treatment than any other group. From the date of the mutational test result, OS (7.1–7.3 months) was similar between the groups. OS from LOT1 (14.0 months) and LOT2 (10.8 months), and TTNT from LOT1 (6.9 months) and LOT2 (6.3 months) was numerically longer for the KRAS G12C mutated group compared to any other group. However, from LOT1 and LOT2, the OS and TTNT were comparable when stratifying the groups by PD-L1 expression level. Regardless of the mutational group, OS was markedly longer for patients with high PD-L1 expression. Conclusion: In patients diagnosed with advanced NSCLC after the implementation of anti-PD-1/L1 therapies, the survival in KRAS G12C mutated patients is comparable to patients with any KRAS mutation, Triple WT, and all NSCLC patients.
KW - Kirsten Rat Sarcoma viral Oncogene homolog DNA with G12C mutation at the protein level (KRAS G12C mutation)
KW - KRAS mutation
KW - Non-Small Cell Lung Cancer (NSCLC)
KW - Overall survival
KW - Programmed Death Ligand 1 (PD-L1) expression
KW - Real world evidence
U2 - 10.1016/j.lungcan.2023.02.021
DO - 10.1016/j.lungcan.2023.02.021
M3 - Journal article
C2 - 36868178
AN - SCOPUS:85149370427
VL - 178
SP - 172
EP - 182
JO - Lung Cancer
JF - Lung Cancer
SN - 0169-5002
ER -
ID: 366380271